Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : Accelerated Cure Project Launches Collaborative Research Program with Regeneron Genetics Center to Sequence DNA of Multiple Sclerosis Patients

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/23/2018 | 10:14pm CET

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- The Accelerated Cure Project for Multiple Sclerosis (ACP) announced a collaboration with the Regeneron Genetics Center (RGC), a wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., that will sequence the entire exome region of all DNA samples in the ACP biospecimen repository. The exome is the protein-coding region of the human genome, which represents under 2 percent of the genome, but contains a majority of the known inherited genetic variants associated with all diseases (see also Accelerated Cure Project for Multiple Sclerosis).

The RGC will use its fully-automated sample preparation and data processing, and cutting-edge cloud-based informatics to sequence the exomes in DNA samples from the ACP Repository, an open-access research resource for qualified investigators with biosamples from over 3,200 participants. Sample donors include people diagnosed with multiple sclerosis (MS), neuromyelitis optica (NMO), and other related diseases, as well as control participants. The data will subsequently be returned to ACP and eventually made available to all qualified investigators for further studies, which can take advantage of the detailed patient information that accompanies each sample. This includes medical, epidemiological and treatment data and neurologist documentation of diagnostic and monitoring tests.

Keywords for this news article include: Genetics, Neurology, DNA Research, Epidemiology, Neuroimmunology, Health and Medicine, CNS Demyelinating Autoimmune Disease, Demyelinating Diseases and Conditions, Immune System Diseases and Conditions, Accelerated Cure Project for Multiple Sclerosis, Autoimmune Diseases and Conditions of the Nervous System.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
10:14pREGENERON PHARMACEUTICALS : Accelerated Cure Project Launches Collaborative Rese..
AQ
07:56pSTUDIES IN THE AREA OF BREAST CANCER : Novel targets...
AQ
02/15REGENERON PHARMACEUTICALS : Patent Application Titled "Novel Cho Integration Sit..
AQ
02/15REGENERON PHARMACEUTICALS : Patent Issued for Production of Fertile XY Female Mi..
AQ
02/14NASDAQ 100 MOVERS : Regn, bidu
AQ
02/14REGENERON PHARMACEUTICALS : Announces Appointment of Marion McCourt as Senior Vi..
AQ
02/12REGENERON PHARMACEUTICALS : Today’s Research Reports on Trending Tickers: Regene..
AC
02/12REGENERON PHARMACEUTICALS : Announces Appointment of Marion McCourt as Senior Vi..
PR
02/08REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
02/08REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Inc. Deta..
AQ
More news
News from SeekingAlpha
12:06pSome Thoughts On The Continued Negative Media For Regeneron 
02/22Regeneron's Eylea sees uptick in side effects, cause unknown 
02/21UNDERVALUED AND ATTRACTIVE : Pick Up Novartis In 2018 
02/21Premarket analyst action - healthcare 
02/19Regeneron Annual Report, Earnings Forecast And Stock Valuation 
Financials ($)
Sales 2018 6 368 M
EBIT 2018 2 492 M
Net income 2018 1 711 M
Finance 2018 3 230 M
Yield 2018 -
P/E ratio 2018 21,68
P/E ratio 2019 18,55
EV / Sales 2018 4,85x
EV / Sales 2019 4,09x
Capitalization 34 113 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 420 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-15.55%34 113
GILEAD SCIENCES12.63%105 375
VERTEX PHARMACEUTICALS5.36%39 931
BIOVERATIV INC93.47%11 243
GENMAB16.62%10 344
BLUEBIRD BIO INC16.45%10 168